Hematologic Oncology | Specialty

R/R DLBCL: Second-Line Treatment Options

February 5th 2021

DLBCL: Treating Patients Following Relapse on Frontline Therapy

February 5th 2021

Selinexor Approved in Israel for Multiple Myeloma, DLBCL

February 4th 2021

February 4, 2021 — The Israeli Ministry of Health has approved selinexor for the treatment of patients with multiple myeloma or diffuse large B-cell lymphoma.

Gilteritinib Receives Conditional Approval in China for FLT3+ AML

February 4th 2021

February 4, 2021 - The China National Medical Products Administration has granted a conditional approval to gilteritinib for use in adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation detected by a validated test.

2020 Approvals Expand Access to Care for Patients Across Tumor Types

February 4th 2021

In a year marked by collaboration and innovation, therapeutic developments in oncology care once again dominated the novel drug approvals in 2020.

Surge of New Drugs Fuels Optimism in Pediatric Oncology

February 4th 2021

The landscape for pediatric oncology drugs expanded dramatically last year, with 8 new drugs or indications specifically approved for children compared with just 47 for treatment and supportive care products from the early 1950s through 2019.

Managing MRD-Positive Acute Lymphoblastic Leukemia

February 4th 2021

Treatment of Acute Lymphoblastic Leukemia in the Community Setting

February 4th 2021

A Look at the ELEVATE-TN and ASCEND Trials

February 3rd 2021

Dr Stilgenbauer explains the ELEVATE-TN and ASCEND clinical trials; Dr Brown highlights the adverse effects seen with acalabrutinib.

Acalabrutinib in the Treatment of Chronic Lymphocytic Leukemia

February 3rd 2021

Experts provide insight on the use of acalabrutinib in treating chronic lymphocytic leukemia.

Clinical Trials With BTK Inhibitors in Chronic Lymphocytic Leukemia

February 3rd 2021

Dr Brown provides a brief overview of data available that support the use of Bruton’s tyrosine kinase inhibitors in treating chronic lymphocytic leukemia; Dr Stilgenbauer comments on mitigating and managing adverse effects in the treatment of chronic lymphocytic leukemia.

BTK Inhibitors in Treatment of Chronic Lymphocytic Leukemia

February 3rd 2021

Dr Ghia provides an in-depth conversation on the use of Bruton tyrosine kinase inhibitors in treating chronic lymphocytic leukemia.

Individualized Induction Therapy for NDMM

February 3rd 2021

Approaching Early Treatment of High-Risk SMM

February 3rd 2021

Pediatric Leukemia Pioneer Emil J. Freireich Dies at 93

February 2nd 2021

February 2, 2021 - Emil J. Freireich, MD, DSc, a founding father of modern clinical cancer research and the 2015 Giants of Cancer Care award winner for Lymphoid Neoplasms, has died at age 93.

Acalabrutinib and Zanubrutinib for Relapsed MCL

February 2nd 2021

BTK Inhibitors for Relapsed Mantle Cell Lymphoma

February 2nd 2021

MRD Could Prove to Be a Valuable Tool in Multiple Myeloma

February 1st 2021

Marc J. Braunstein, MD, PhD, discusses the current landscape of newly diagnosed multiple myeloma and the utility of minimal residual disease in the research sphere.

Pembrolizumab Approaches EU Approval for Expanded Indication in Relapsed/Refractory Hodgkin Lymphoma

February 1st 2021

February 1, 2020 - The European Medicines Agency’s Committee of Medicinal Products for Human Use has recommended a label expansion for pembrolizumab for use as a single agent in adult and pediatric patients aged 3 years and older with relapsed/refractory classical Hodgkin lymphoma for whom autologous stem cell transplant has failed or following at least 2 previous therapies when ASCT is not an option.

Influencing Factors to Initially Targeting BCMA in MM

February 1st 2021